Treatment of Acute Liver Injury through Selective Tropism of <i>High Mobility Group Box 1</i> Gene-Silenced Large Peritoneal Macrophages.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40099379.
- Also identified by DOI 10.1021/acsnano.4c18345 and PMC identifier 11966748.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tissue-resident macrophages (TRMs) are attractive cells to therapeutically deliver oligonucleotide and other gene-expression modifying modalities to treat a wide array of diseases ranging from inflammatory to autoimmune, and even cancer. Here, we focus on TRMs located inside the peritoneal cavity lining the abdomen that selectively express a transcription factor GATA6 called large peritoneal macrophages (GLPMs) and successfully demonstrate functional GLPM-selective delivery of a Cy5-fluorophore-labeled siRNA encapsulated in C12-200 cationic-lipidoid-based nanoparticles (siRNA-Cy5 (C12-200)). Despite being TRMs, GLPMs possess a specific migratory ability to peritoneally located liver tissue upon injury incited by acetaminophen (APAP) overdose in mice. A rapid, liver injury-driven tropism of GLPMs carrying siRNA-Cy5 (C12-200) was seen via systemic circulation, which was elegantly demonstrated by using a noninvasive live-cell tracking technique called diffuse <i>in vivo</i> flow cytometry (DiFC). Finally, RNAi-mediated silencing of a well-known pro-inflammatory damage-associated molecular pattern (DAMP) <i>High Mobility Group Box-1</i> (HMGB1) gene in GLPMs led to the mitigation of liver injury and inflammation via prevention of GLPM modulation to a pro-inflammatory state, which further translated into significant protection from APAP-driven liver injury and a reduction in liver circulating pro-inflammatory cytokines owing to a muted inflammatory response to acute liver injury. Moreover, silencing HMGB1 by a GalNAc-conjugated hepatocyte-targeting siRNA did not reciprocate the findings, further solidifying our results. Together, our data suggested that GLPMs act as delivery carriers by rapidly bringing lipid nanoparticle-encapsulated RNAi modalities to the injured liver and have emerged as a therapeutically viable strategy to address inflammatory diseases, especially those that are more acute in nature.
Medical subject headings
- HMGB1 Protein
- RNA, Small Interfering
- Macrophages, Peritoneal
- Gene Silencing
- Chemical and Drug Induced Liver Injury